Tuesday, August 22, 2023
Mainz Biomed NV, a leader in molecular genetics diagnostics focused on early cancer detection, has successfully introduced its ColoAlert® product in Poland through a strategic collaboration with testDNA Sp. z o. o. Sp. K (testDNA). This partnership marks a significant advancement in delivering innovative testing solutions for colorectal cancer (CRC) to underserved populations.
ColoAlert®, Mainz Biomed's flagship product, offers an easy-to-use at-home screening test with high efficacy for early-stage colorectal cancer detection. The collaboration with testDNA aims to broaden the accessibility of this groundbreaking technology, providing improved screening tools that have the potential to save numerous lives across Poland.
Established in 2003, testDNA is a prominent player in DNA-based testing services in Poland. As an accredited research laboratory endorsed by the Polish Center for Accreditation, it is headquartered in Katowice, Poland, and boasts a vast network of over 300 collection points nationwide. With a diverse portfolio, testDNA is renowned for delivering cutting-edge genetic testing solutions tailored to individual requirements.
The imperative for diverse colorectal cancer (CRC) screening options is underscored by data from the World Cancer Research Fund International, which ranks Poland as the 7th country globally with the highest CRC mortality rate. With a population exceeding 21 million individuals aged 40 and above, there exists substantial market potential for ColoAlert®. This is particularly pertinent considering historically low participation rates in CRC screening, largely centered around colonoscopies. A recent NordICC study, published in the New England Journal of Medicine, unveiled that a mere 33% of those invited for colonoscopy screening actually participated. This highlights the need for alternative, less invasive, and more convenient screening methods that individuals can perform in the comfort of their homes.
Darin Leigh, Chief Commercial Officer of Mainz Biomed, underscores the significance of this partnership: "Our collaboration with testDNA to enter the Polish market signifies a pivotal milestone in our mission to make ColoAlert® accessible to individuals at risk of colorectal cancer. Together, we are positioned to catalyze transformation in Poland's existing cancer screening landscape, offering timely interventions that hold the potential to save lives."